Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in RNA therapeutics, allergy and viral infections, and inner ear disorders. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol “CYTO.”